Last reviewed · How we verify
AZD4635
AZD4635 is a small molecule inhibitor of the adenosine A2A receptor.
AZD4635 is a small molecule inhibitor of the adenosine A2A receptor. Used for Non-small cell lung cancer.
At a glance
| Generic name | AZD4635 |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | adenosine A2A receptor antagonist |
| Target | adenosine A2A receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting the adenosine A2A receptor, AZD4635 modulates signaling pathways involved in inflammation and immune responses, which may have therapeutic benefits in certain diseases.
Approved indications
- Non-small cell lung cancer
Common side effects
Key clinical trials
- Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study (PHASE1, PHASE2)
- An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer (PHASE2)
- A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC. (PHASE2)
- A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies (PHASE1)
- A Study to Assess the Effect of Fluvoxamine and Smoking on Pharmacokinetics ( the Movement of Drugs Within the Body) of AZD4635 in Healthy Volunteers (PHASE1)
- A Phase I Study of AZD4635 in Japanese Patients With Advanced Solid Malignancies (PHASE1)
- AZD4635 Relative Bioavailability Study (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD4635 CI brief — competitive landscape report
- AZD4635 updates RSS · CI watch RSS
- AstraZeneca portfolio CI